Product Description
Mechanisms of Action: PBP Binder
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Injection
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: China | India
Approved Indications: None
Known Adverse Events: None
Company: Replidyne
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Bronchitis, Chronic|Pneumonia, Bacterial|Respiratory Tract Infections|Pneumonia
Phase 2: Pneumonia, Bacterial|Tuberculosis, Pulmonary|Otitis Media
Phase 1: Tuberculosis|Mycobacterium Infections
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CTR20233579 | N/A |
Completed |
Healthy Volunteers |
2024-01-22 |
|
| CTR20232271 | N/A |
Completed |
Tonsillitis|Burns Unspecified|Lymphadenitis|Pneumonia|Pharyngitis|Chronic Periodontitis|Orchitis|Prostatitis|Inflammation|Pyelonephritis|Otitis Media|Mastitis|Lung Abscess|Skin Ulcer|Otitis Externa|Corneal Ulcer|Bronchitis, Chronic|Sinusitis|Lymphangitis|Dacryocystitis|Keratitis |
2023-08-29 |
|
| CTR20223323 | N/A |
Completed |
Pneumonia|Influenza, Human |
2023-03-08 |
|
| CTR20222096 | N/A |
Completed |
Burns Unspecified|Pneumonia|Sinusitis|Osteoma|Chronic Cough|Influenza, Human|Scarlet Fever|Skin Diseases, Infectious|Pericoronitis|Tonsillitis|Otitis Externa|Lymphangitis|Pharyngitis|Bronchitis, Chronic|Uterine Diseases|Enterobacteriaceae Infections|Otitis Media|Dacryocystitis|Mastitis|Whooping Cough|Proteus Infections|Prostatitis|Pyelonephritis|Haemophilus Infections|Inflammation|Lung Abscess|Epididymitis|Chronic Periodontitis|Escherichia coli Infections|Corneal Ulcer|Skin Ulcer|Lymphadenitis|Klebsiella Infections |
2022-10-31 |